Achilles Therapeutics plc (NASDAQ:ACHL) Sees Significant Decrease in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 37,800 shares, a decline of 49.5% from the March 31st total of 74,800 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 770,200 shares, the days-to-cover ratio is presently 0.0 days.

Achilles Therapeutics Stock Down 1.2 %

ACHL opened at $0.77 on Friday. The stock has a market capitalization of $30.88 million, a price-to-earnings ratio of -0.45 and a beta of 1.09. The firm has a 50 day moving average price of $1.11 and a 200-day moving average price of $0.96. Achilles Therapeutics has a twelve month low of $0.74 and a twelve month high of $1.76.

Achilles Therapeutics (NASDAQ:ACHL) last announced its earnings results on Thursday, April 4th. The company reported ($0.46) earnings per share for the quarter. As a group, analysts expect that Achilles Therapeutics will post -1.34 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Achilles Therapeutics stock. Vestal Point Capital LP acquired a new position in Achilles Therapeutics plc (NASDAQ:ACHL) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 108,083 shares of the company’s stock, valued at approximately $96,000. Vestal Point Capital LP owned 0.27% of Achilles Therapeutics as of its most recent SEC filing. 56.38% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ACHL has been the topic of several recent analyst reports. Piper Sandler reissued a “neutral” rating and set a $2.00 price objective (down from $8.00) on shares of Achilles Therapeutics in a research report on Friday, April 5th. Chardan Capital cut their price target on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, April 5th.

Achilles Therapeutics Company Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.